YahooOctober 27, 2026 at 3:14 AM NY12 Hours Ago
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
ImmunityBio expects November results from a 366-patient Anktiva trial and plans a fourth-quarter FDA filing.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
